| Company Name: |
ShangHai Caerulum Pharma Discovery Co., Ltd.
|
| Tel: |
18149758185 18149758185 |
| Email: |
sales-cpd@caerulumpharma.com |
| Products Intro: |
Product Name:Berberine (chloride hydrate)
CAS:68030-18-2
Purity:98% Package:1g;10g;100g
|
| Company Name: |
Beijing Jin Ming Biotechnology Co., Ltd.
|
| Tel: |
010-60605840 18892239720 |
| Email: |
psaitong@jm-bio.com |
| Products Intro: |
Product Name:Berberine chloride hydrate
CAS:68030-18-2
Purity:98% Package:100mg
|
| Company Name: |
Guangzhou Younan Technology Co., Ltd
|
| Tel: |
020-82000279 18988968278 |
| Email: |
sales@ubiochem.com |
| Products Intro: |
Product Name:Berberine chloride hydrate
CAS:68030-18-2
Purity:98% Package:5mg;10mg;50mg;100mg
|
|
| | Berberine chloride hydrate Basic information |
| | Berberine chloride hydrate Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: ≥ 3.9 mg/mL (10.00 mM); Water: 1.25 mg/mL (3.21 mM) | | form | Solid | | color | Light yellow to yellow |
| | Berberine chloride hydrate Usage And Synthesis |
| Biological Activity | Berberine chloride hydrate (Natural Yellow 18 chloride hydrate) is an alkaloid isolated from Chinese herbal medicine Coptis chinensis and is commonly used as an antibiotic. Berberine chloride hydrate induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. | | in vitro | Berberine chloride hydrate ( Natural Yellow 18 chloride hydrate; 1.25-160 μM; 72 hours) has potential inhibitory effects on the proliferation of four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29.
Berberine chloride hydrate (1.25-160 μM; 24-72 hours) induces a time- and dose-dependent inhibition of LoVo cell growth.
LoVo cells are exposure to Berberine chloride hydrate (10-80 μM) for 24 h. Cell cycle analysis of 40 μM Berberine-treated LoVo cells by flow cytometry shows accumulation of cells in the G2/M phase.
Berberine chloride hydrate (10-80 μM) suppresses cyclin B1, cdc2 and cdc25c protein expression after 24 h, especially at the dose of 80.0 μM. Cell Proliferation Assay | Cell Line: | Four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29 | | Concentration: | 1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM | | Incubation Time: | 72 hours | | Result: < /td> | Inhibited the proliferation of four cell lines. The IC 50 ranged from 40.8±4.1 μM (LoVo) to 98.6±2.9 μM (HCT116). | Cell Proliferation Assay | Cell Line: | Colorectal carcinoma cell lines LoVo | | Concentration: | 1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM | | Incubation Time: | 24, 48, 72 hours | | Result: | Induced a time- and dose-dependent inhibition of cell growth. By 72 h, 160.0 μM induced 71.1±1.9 % growth inh ibitions in LoVo cells. | Cell Cycle Analysis | Cell Line: | LoVo cells | | Concentration: | 0, 10, 20, 40, or 80 μM | | Incubation Time: | 24 hours | | Result: | Exposure to 40.0 μM induced G2/M-phase cell cycle arrest, an increase in the G2/M-phase population and a progressive decline in the G1 population. | |
Western Blot Analysis | Cell Line: | LoVo cells | | Concentration: | 10, 20, 40, or 80 μM | | Incubation Time: | 24 hours | | Result: | Suppressed cyclin B1, cdc2 and cdc25c protein expression. | < /tr> |